These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33595888)

  • 1. Immunotherapy in lung cancer.
    Montenegro GB; Farid S; Liu SV
    J Surg Oncol; 2021 Mar; 123(3):718-729. PubMed ID: 33595888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Advanced Lung Cancer.
    Huang J; Reckamp KL
    Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
    Rusch VW; Chaft J; Hellmann M
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.
    John T
    Asia Pac J Clin Oncol; 2015 Apr; 11 Suppl 1():2-8. PubMed ID: 25913639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
    Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M
    Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer.
    Wang L; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2020 Feb; 79():106088. PubMed ID: 31896512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Li S; Zhang C; Pang G; Wang P
    Front Immunol; 2020; 11():603157. PubMed ID: 33178229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
    Zhang D; Huang J; Zhang C; Guan Y; Guo Q
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.